US Broker Ratings

Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring the 119% Potential Upside Amid Strong Buy Ratings

For investors eyeing opportunities in the biotechnology sector, Denali Therapeutics Inc. (DNLI) presents a compelling case with its innovative approach to treating neurodegenerative diseases. Headquartered in South San Francisco, California,..

Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: A 39.55% Potential Upside Beckons Investors

Amneal Pharmaceuticals, Inc. (AMRX), a prominent player in the healthcare sector, is garnering attention from investors due to its substantial potential upside. With a market capitalization of $3.92 billion and..

CG Oncology, Inc. (CGON) Investor Outlook: Analyzing a 132.95% Potential Upside in Biotech

CG Oncology, Inc. (CGON), a prominent player in the biotechnology sector, is capturing investor attention with its compelling potential upside of 132.95%. This late-stage clinical biopharmaceutical company is focused on..

Sotera Health Company (SHC) Stock Analysis: Navigating a 24.89% Potential Upside in Healthcare

Sotera Health Company (NASDAQ: SHC) stands out in the healthcare sector, particularly in the diagnostics and research industry. With a market capitalization of $3.3 billion, this Ohio-based company is a..

Select Medical Holdings Corp (SEM) Stock Analysis: A 37% Upside Potential with Strong Buy Ratings

Select Medical Holdings Corporation (NYSE: SEM), a prominent player in the healthcare sector, is capturing investor attention not only with its robust market position but also with a compelling potential..

Metsera, Inc. (MTSR) Stock Analysis: Exploring a Potential 29.50% Upside in the Biotech Industry

For investors seeking opportunities in the burgeoning field of biotechnology, Metsera, Inc. (NASDAQ: MTSR) presents an intriguing prospect. With its focus on developing innovative treatments for obesity and related metabolic..

Veracyte, Inc. (VCYT) Stock Analysis: Unpacking the 53% Upside Potential

For investors navigating the healthcare sector, Veracyte, Inc. (NASDAQ: VCYT) presents an intriguing case with its robust growth potential and a substantial upside forecasted by analysts. Operating within the diagnostics..

Surgery Partners, Inc. (SGRY) Stock Analysis: Exploring a 39.58% Potential Upside for Investors

Surgery Partners, Inc. (NASDAQ: SGRY), a prominent player in the healthcare sector specializing in medical care facilities, offers an intriguing investment opportunity. With a market capitalization of $2.88 billion, this..

GeneDx Holdings Corp. (WGS) Stock Analysis: Exploring a 25.88% Potential Upside in Genomics Innovation

GeneDx Holdings Corp. (NASDAQ: WGS) is making waves in the healthcare sector, specifically within the diagnostics and research industry. Based in Stamford, Connecticut, GeneDx specializes in pediatric and rare disease..

Concentra Group Holdings Parent (CON) Stock Analysis: A Healthcare Powerhouse with 38% Upside Potential

For investors seeking opportunities in the healthcare sector, Concentra Group Holdings Parent (NASDAQ: CON) emerges as a compelling candidate. With a market capitalization of $2.59 billion, Concentra operates within the..

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: Insights into Its 13.39% Potential Upside

For investors seeking opportunities in the healthcare sector, DENTSPLY SIRONA Inc. (NASDAQ: XRAY) presents a compelling case with its diverse offerings in dental and healthcare consumables. Despite its recent challenges,..

Alvotech (ALVO) Stock Analysis: Exploring a 101% Potential Upside in the Biosimilar Market

Alvotech (NASDAQ: ALVO), a Luxembourg-based biosimilar manufacturer, is capturing investor attention with its impressive 101.12% potential upside, as per analyst targets. With a market cap of $2.75 billion, the company..

LifeStance Health Group, Inc. (LFST) Stock Analysis: Exploring a 93.81% Potential Upside

LifeStance Health Group, Inc. (NASDAQ: LFST) has captured the attention of investors with its intriguing potential upside of 93.81%. As a pivotal player in the healthcare sector, focusing on outpatient..

Envista Holdings Corporation (NVST) Stock Report: Navigating a -4.93% Potential Downside Amidst Mixed Analyst Ratings

Envista Holdings Corporation (NYSE: NVST), a prominent player in the healthcare sector specializing in dental products, presents a complex investment profile for potential investors. With a market capitalization of $3.39..

Warby Parker Inc. (WRBY) Investor Outlook: Navigating Strong Revenue Growth Amid Challenges

Warby Parker Inc. (NYSE: WRBY), a leading eyewear retailer headquartered in New York, has carved a niche in the healthcare sector, specifically within the medical instruments and supplies industry. With..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Strong Buy Ratings Signal a Promising 24.93% Upside Potential

Protagonist Therapeutics, Inc. (PTGX) has caught the attention of investors with its pronounced potential for growth within the biotechnology sector. Headquartered in Newark, California, this biopharmaceutical company specializes in developing..

Merus N.V. (MRUS) Stock Analysis: Exploring a 62% Potential Upside in Innovative Oncology Solutions

Merus N.V. (NASDAQ: MRUS), a clinical-stage biotechnology company based in Utrecht, Netherlands, is capturing investor attention with its promising drug pipeline and significant potential upside, currently estimated at 62.17%. Operating..

Zai Lab Limited (ZLAB): Investor Outlook on a Biotech Powerhouse with 58.58% Upside Potential

Zai Lab Limited (NASDAQ: ZLAB), a prominent player in the biotechnology sector, has been making waves in the healthcare industry with its innovative approach to tackling critical medical conditions. Based..

PROCEPT BioRobotics (PRCT) Stock Analysis: Unveiling a 32% Potential Upside in the Healthcare Sector

PROCEPT BioRobotics Corporation (NASDAQ: PRCT), a player in the burgeoning medical devices industry, is gaining significant attention from investors due to its innovative advancements in surgical robotics. Specializing in urology,..

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: A 207% Upside Potential Awaits Investors

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) continues to capture the attention of investors with its promising pipeline and substantial growth potential. As a key player in the biotechnology industry, Ultragenyx focuses..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds